Based on the important role of lipophagy in fatty liver, the treatment of fatty liver with lipophagy has become a hot topic in recent years [23].The key negative regulator of lipophagy, mTORC1, has recently become a targeted regulator of nonalcoholic fatty liver disease [24].The antidiabetic drug metformin can mediate tristetraprolin (TTP) to inhibit mTORC1, promote hepatocyte lipophagy, and alleviate hepatic steatosis [25]. This evidence concerns the gene ZFP36 and metabolic dysfunction-associated steatotic liver disease.